Online inquiry

IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12276MR)

This product GTTS-WQ12276MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Renal Cell Carcinoma (RCC), Merkel cell carcinoma (MCC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12276MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11187MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI0562
GTTS-WQ10772MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA M-70
GTTS-WQ7335MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA FPA-150
GTTS-WQ6085MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ11609MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MGD-006
GTTS-WQ6580MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA DC-1630423
GTTS-WQ134MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ13062MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PEG-IFN-SA
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW